46 related articles for article (PubMed ID: 38482898)
1. Bimekizumab in psoriasis: a monocentric study evaluating short- and mid-term effectiveness and safety profile in a real-world setting.
Rompoti N; Stefanaki I; Panagakis P; Vavouli C; Politou M; Papoutsaki M; Befon A; Koutsa F; Lazou E; Koumprentziotis IA; Chasapi V; Stratigos A; Nicolaidou E
Arch Dermatol Res; 2024 Apr; 316(5):133. PubMed ID: 38662223
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry.
Papp KA; Gooderham M; Lynde C; Brassard D; Al-Mohammedi F; Prajapati VH; Delorme I; Albrecht L; Haydey R; Alam MS; Beecker J; Siddha S; Maguin M; Farag MS; Vieira A; Rihakova L; Langley RG
Arch Dermatol Res; 2024 Jun; 316(7):362. PubMed ID: 38850346
[TBL] [Abstract][Full Text] [Related]
3. Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO).
Pinter A; Eyerich K; Costanzo A; Garrelts A; Schuster C; Mert C; Lampropoulou A; Fotiou K; Maul JT; Papp KA
J Dermatolog Treat; 2024 Dec; 35(1):2350227. PubMed ID: 38797734
[TBL] [Abstract][Full Text] [Related]
4. Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trials.
Blauvelt A; Armstrong A; Merola JF; Strober B; de Cuyper D; Peterson L; Davies O; Stark JL; Lebwohl M
J Am Acad Dermatol; 2024 Jul; 91(1):72-81. PubMed ID: 38447700
[TBL] [Abstract][Full Text] [Related]
5. Analysis of factors influencing target PASI responses and side effects of methotrexate monotherapy in plaque psoriasis: a multicenter study of 1521 patients.
Erduran F; Emre S; Hayran Y; Adışen E; Polat AK; Üstüner P; Öztürkcan S; Öztürk P; Ermertcan AT; Selçuk LB; Aksu EK; Akbaş A; Kalkan G; Demirseren D; Kartal SP; Topkarcı Z; Kılıç A; Yaldız M; Aytekin S; Hızlı P; Gharehdaghi S; Borlu M; Işık L; Botsalı BR; Solak EÖ; Albayrak H; Gönülal M; Balcı DD; Polat M; Daye M; Ataseven A; Yıldız S; Özer İ; Zorlu Ö; Doğan S; Erdemir VA; Dikicier BS
Arch Dermatol Res; 2024 May; 316(6):278. PubMed ID: 38796658
[TBL] [Abstract][Full Text] [Related]
6. Safety and effectiveness of guselkumab in Japanese patients with psoriasis: 20-week interim analysis of a postmarketing surveillance study.
Tada Y; Sugiura Y; Kamishima M; Tanaka Y; Tsuchiya H; Masuda J; Yamanaka K
J Dermatol; 2024 Jun; 51(6):779-790. PubMed ID: 38747075
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study - IL PSO (Italian landscape psoriasis).
Gargiulo L; Ibba L; Cascio Ingurgio R; Malagoli P; Amoruso F; Balato A; Bardazzi F; Brianti P; Brunasso G; Burlando M; Cagni AE; Caproni M; Carrera CG; Carugno A; Caudullo F; Cuccia A; Dapavo P; Di Brizzi EV; Dini V; Gaiani FM; Gisondi P; Guarneri C; Lasagni C; Licata G; Loconsole F; Marzano AV; Megna M; Mercuri SR; Musumeci ML; Orsini D; Ribero S; Ruffo Di Calabria V; Satolli F; Strippoli D; Travaglini M; Trovato E; Venturini M; Zichichi L; Valenti M; Costanzo A; Narcisi A
J Dermatolog Treat; 2024 Dec; 35(1):2350760. PubMed ID: 38714323
[TBL] [Abstract][Full Text] [Related]
8. Bimekizumab for the Treatment of Plaque Psoriasis with Involvement of Genitalia: A 16-Week Multicenter Real-World Experience - IL PSO (Italian Landscape Psoriasis).
Orsini D; Malagoli P; Balato A; Bianchi L; Brianti P; Buononato D; Burlando M; Caldarola G; Campanati A; Campione E; Carrera CG; Carugno A; Cusano F; Dapavo P; Dattola A; De Simone C; Dini V; Esposito M; Fargnoli MC; Gaiani FM; Gargiulo L; Gisondi P; Giunta A; Ibba L; Lasagni C; Loconsole F; Maione V; Mortato E; Marzano AV; Maurelli M; Megna M; Mercuri SR; Narcisi A; Offidani A; Paolino G; Parodi A; Pellacani G; Potestio L; Quaglino P; Richetta AG; Romano F; Sena P; Venturini M; Assorgi C; Costanzo A
Dermatol Pract Concept; 2024 Apr; 14(2):. PubMed ID: 38416060
[TBL] [Abstract][Full Text] [Related]
9. Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 16-week multicenter retrospective study.
Rimke A; Sood S; Rankin BD; Abduelmula A; Georgakopoulos JR; Maliyar K; Bagit A; Leung F; Stark LA; Vender R; Yeung J; Prajapati VH
J Am Acad Dermatol; 2024 Apr; ():. PubMed ID: 38649098
[No Abstract] [Full Text] [Related]
10. Rapid response on facial psoriasis to bimekizumab: case series.
Bernardini N; Dattola A; Caldarola G; Orsini D; Assorgi C; D'Amore A; Maretti G; Richetta AG; Tolino E; Skroza N; Potenza C
Drugs Context; 2024; 13():. PubMed ID: 38817804
[TBL] [Abstract][Full Text] [Related]
11. Real-world effectiveness and safety of bimekizumab for hidradenitis suppurativa: An ambispective observational study.
Mansilla-Polo M; Pons-Benavent M; Fernández-Crehuet P; Vilarrasa E; Albanell-Fernández C; Morales-Tedone E; Rausell-Félix F; Alcalá-García R; Matellanes-Palacios M; Martín-Ezquerra G; Alfageme F; Ciudad-Blanco C; López-Villaescusa MT; Garbayo-Salmons P; Martorell A; Escutia-Muñoz B; Navarro-Blanco F; Martín-Torregrosa D; Cuenca-Barrales C; Molina-Leyva A; Botella-Estrada R
Australas J Dermatol; 2024 Jun; ():. PubMed ID: 38895808
[TBL] [Abstract][Full Text] [Related]
12. Bimekizumab-bkzx.
Mitrić MM
Clin Ther; 2024 Apr; 46(4):379-380. PubMed ID: 38705824
[No Abstract] [Full Text] [Related]
13. Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 52-week multicenter retrospective study.
Sood S; Rimke A; Rankin BD; Abduelmula A; Georgakopoulos JR; Maliyar K; Bagit A; Leung F; Stark LA; Devani AR; Vender R; Yeung J; Prajapati VH
J Am Acad Dermatol; 2024 Jun; ():. PubMed ID: 38885841
[No Abstract] [Full Text] [Related]
14. Bimekizumab-bkzx.
Am J Health Syst Pharm; 2024 Apr; 81(8):245-247. PubMed ID: 38153141
[No Abstract] [Full Text] [Related]
15. Corrigendum: "Comparative Effectiveness of Bimekizumab in Psoriatic Arthritis: A Model-Based Meta-Analysis of American College of Rheumatology Response Criteria".
Clin Pharmacol Ther; 2024 Jun; ():. PubMed ID: 38860726
[No Abstract] [Full Text] [Related]
16. The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials.
Potestio L; Martora F; Lauletta G; Vallone Y; Battista T; Megna M
Clin Cosmet Investig Dermatol; 2024; 17():829-842. PubMed ID: 38616886
[TBL] [Abstract][Full Text] [Related]
17. Real-world effectiveness and safety of bimekizumab in Japanese patients with psoriasis: A single-center retrospective study.
Hagino T; Saeki H; Fujimoto E; Kanda N
J Dermatol; 2024 May; 51(5):649-658. PubMed ID: 38482898
[TBL] [Abstract][Full Text] [Related]
18. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.
Papp KA; Merola JF; Gottlieb AB; Griffiths CEM; Cross N; Peterson L; Cioffi C; Blauvelt A
J Am Acad Dermatol; 2018 Aug; 79(2):277-286.e10. PubMed ID: 29609013
[TBL] [Abstract][Full Text] [Related]
19. Bimekizumab versus Adalimumab in Plaque Psoriasis.
Warren RB; Blauvelt A; Bagel J; Papp KA; Yamauchi P; Armstrong A; Langley RG; Vanvoorden V; De Cuyper D; Cioffi C; Peterson L; Cross N; Reich K
N Engl J Med; 2021 Jul; 385(2):130-141. PubMed ID: 33891379
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
